Avotaciclib sulfate
Based on 3 publication(s) in Google Scholar
Avotaciclib (BEY1107) sulfate is an orally active cyclin-dependent kinase 1 (CDK1) inhibitor. Avotaciclib sulfate can inhibit the proliferation and induce apoptosis of tumor cells. Avotaciclib sulfate can be used in the research of cancer such as pancreatic cancer and lung cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 1983984-04-8
- Formule: C13H13N7O5S
- Masse moléculaire:379.35
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Avotaciclib sulfate
More
Activité biologique
|
CDK1 |
Avotaciclib (0-64 μM; 48 h) sulfate can inhibit cell proliferation and promote apoptosis in radiotherapy-resistant non-small cell lung cancer cell lines, and the effect is better when combined with PV-1019 (HY-125203)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Non-small cell lung cancer cells (H1437R, H1568R, H1703R and H1869R)
-
Concentration:0, 0.1, 1, 2, 4, 8, 16, 32 and 64 μM
-
Incubation Time:48 h
-
Result:Inhibited the cell viability, with EC50 values of 0.918, 0.580, 0.735 and 0.662 μM for H1437R, H1568R, H1703R and H1869R, respectively.
Chemical Information
-
CAS No. 1983984-04-8
-
Masse moléculaire 379.35
-
Formule C13H13N7O5S
-
SMILES
OC1=CC=C(C2=NC(N)=NC=C2)N=C1C3=NC(N)=NC=C3.O=S(O)(O)=O
-
Synonyms
BEY1107 sulfate
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Clin Sci
Glutamine alleviates immunosuppression in polymicrobial sepsis by augmenting bacterial phagocytosis through sustaining the GFAT-DRP1 dependent mitochondrial calcium dynamics. [Abstract]2025 Oct 22;139(20):1163-1185. PMID: 41082631 -
Cancer Cell Int
Proapoptotic role of CDK1 in overcoming paclitaxel resistance in ovarian cancer cells in response to combined treatment with paclitaxel and duloxetine. [Abstract]2024 Dec 19;24(1):409. PMID: 39702300 -
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)